Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features.
Introduction. Breast cancer with mammographic casting type calcifications, high grade DCIS with an abnormal number of ducts, periductal desmoplastic reaction, lymphocyte infiltration, and tenascin-C (TN-C) overexpression has been proposed to represent a more aggressive form of breast cancer and has been denominated as breast cancer with neoductgenesis. We developed histopathological criteria for neoductgenesis in order to study reproducibility and correlation with other tumour markers. Methods. 74 cases of grades 2 and 3 DCIS, with or without an invasive component, were selected. A combined score of the degree(s) of concentration of ducts, lymphocyte infiltration, and periductal fibrosis was used to classify cases as showing neoductgenesis, or not. Diagnostic reproducibility, correlation with tumour markers, and mammographic features were studied. Results. Twenty-three of 74 cases were diagnosed with neoductgenesis. The kappa value between pathologists showed moderate reproducibility (0.50) (95% CI; 0.41-0.60). Neoductgenesis correlated significantly with malignant type microcalcifications and TN-C expression (P = 0.008 and 0.04) and with ER, PR, and HER2 status (P < 0.00001 for all three markers). Conclusions. We developed histological criteria for breast cancer with neoductgenesis. Neoductgenesis, by our applied histopathological definition was related to more aggressive tumour biology and malignant mammographic calcifications.
Department of Surgical Sciences, Uppsala University, 751 85 Uppsala, Sweden.
Wenjing
0000-0002-1312-6337
W
Zhou
Department of Pathology, Örebro University, 701 85 Örebro, Sweden.
Thomas
T
Sollie
Department of Pathology, Falun Central Hospital, 791 82 Falun, Sweden.
Tibor
0000-0001-8479-0115
T
Tot
Department of Research Oncology, King's College London, London SE1 9RT, UK.
Sarah E
SE
Pinder
Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Rose-Marie
RM
Amini
Department of Oncology, Helsinki University Central Hospital, 00029 Helsinki, Finland.
Carl
C
Blomqvist
Department of Radiology, Oncology and Radiation Science, Uppsala University, 751 85 Uppsala, Sweden.
Marie-Louise
ML
Fjällskog
Department of Surgery, Falun Central Hospital, 791 82 Falun, Sweden.
Gunilla
G
Christensson
Department of Radiology, Oncology and Radiation Science, Uppsala University, 751 85 Uppsala, Sweden.
Shahin
S
Abdsaleh
Department of Surgical Sciences, Uppsala University, 751 85 Uppsala, Sweden ; Department of Surgery, Uppsala Academic Hospital, 751 85 Uppsala, Sweden.
Fredrik
F
Wärnberg